HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Regulus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock opened at $1.56 on Monday. The firm has a market cap of $102.13 million, a price-to-earnings ratio of -1.46 and a beta of 1.63. The stock’s 50-day moving average is $1.55 and its 200-day moving average is $1.82. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities analysts expect that Regulus Therapeutics will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Creative Planning bought a new position in Regulus Therapeutics during the third quarter worth about $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $33,000. Victory Capital Management Inc. boosted its stake in shares of Regulus Therapeutics by 10.4% during the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after acquiring an additional 37,480 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in Regulus Therapeutics in the 2nd quarter valued at $136,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.